It is very important that we have a collaboration with pharmaceutical companies so that we can act as a bridge between patients and the developers of…
In Conversation
We have several agreements in place ... We hope that this combined effort will lead to a number of successful COVID-vaccines that will use our adjuvant…
We have many programs currently in Phase III development. All these medicines are potentially transformative in nature. These are not ‘me too’ drugs that aim to…
My priority leading LEO Pharma Inc. in the US is attracting, developing and retaining members of our team. We have focused on building a company culture…
We want to combine the agility of a biotech with the experience of a Big Pharma company
Our pursuit and pioneering of cutting edge improvements, along with our partnerships with various medical expert KOLs in Hong Kong, are what made us the NIPT…
The more successful and competitive the market in the PD-(L)1 sphere, the greater Genome & Company’s possibilities for collaboration
From an R&D perspective ... what is critical in ophthalmology is the development of a novel drug delivery mechanism
Despite being a relatively new company, in 2019, we raised the most money in our field in China. We are really one of the frontrunners in…
Our solution is akin to capsule coffee. One machine can provide a wide variety of coffee as the coffee capsules themselves have already been pre-mixed and…
We are open to collaborations with different partners in different regions, rather than a comprehensive global deal
We really believe that data is a powerful tool that allows us to tell the stories of patients with rare diseases better
